Dott.ssa Vittorina Zagonel


An essential component of research conducted at IOV is characterized by innovative clinical studies, precision medicine, and translational studies. Retrospective, observational, and interventional studies aimed at optimizing already available treatments and at developing innovative therapies based on molecular characterization and precision medicine are crucial to producing knowledge on optimal patient treatment. Another essential element is the search for predictive and prognostic factors and the use of patient reported outcomes (PROs) to evaluate the impact of new therapies on patients’ quality of life.


Research at the IOV is characterized by a continuous commitment to promotion and participation in pharmacological and non-pharmacological clinical research protocols. The results obtained to date have allowed us to develop and promote cutting-edge skills in the conception, coordination, and management of clinical and translational research initiatives. Collaboration with many Italian oncology departments guarantees competitive recruitment in international trials with innovative drugs. In the field of oncology, the rapid transfer of innovative therapies to the clinical setting guarantees many patients the opportunity to benefit from new real-time care opportunities. The results obtained must be measured and monitored with retrospective protocols, which are a valuable source of data for exploratory hypotheses to be verified longitudinally. The clinical research line is the point of arrival and departure for translational projects, and it is strictly related to the other IOV research lines.


Clinical research is intrinsic to the mission of an IRCCS. The strategic objective is to implement translational research, and to identify predictive response indicators to optimize the type and duration of innovative therapies (e.g. Immunotherapy), in order to guarantee effective and socially sustainable treatments. These aspects cannot be separated from the patient in his or her entirety; prevention, rehabilitation, nursing and psychological support, nutrition, pain relief, and quality of life find a perfect integration in research programs, designed with the same methodological rigor as that for clinical trials.

Global goals

  1. to perform research projects at each decision-making node of the therapeutic-care pathway: molecular characterization of tumors, translational research, personalization of care, quality of life;
  2. to expand non-pharmacological trials; retrospective and outcome analyses such as monitoring and verification of the results obtained;

Expected results

  • Progressive increase in the number of active clinical trials.
  • To design and participate in independent research study proposals and implement leadership of national and international initiatives.
  • To drive translational and non-pharmacological studies, including those aimed to detect predictive indicators of response and use of PROs as a parameter of quality of life.
  • Dissemination of results at national and international level.
  • increased participation, with significant roles for IOV staff, within Italian and international collaborative networks (e.g. cooperative groups, ACC, OECI, EORTC, etc).
Top 15 pubblicazioni 2018 linea 4
TitoloAutoriRivistaIF grezzo
Cabozantinib in patients with advanced and progressing hepatocellular carcinomaAbou-Alfa Ghassan K., Meyer Tim, Cheng Ann Lii, El-Khoueiry Anthony B., Rimassa Lorenza, Ryoo Baek Yeol, Cicin Irfan, Merle Philippe, Chen Yen Hsun, Park Joong Won, Blanc Jean Frederic, Bolondi Luigi, Kl¿¿mpen Heinz Josef, Chan Stephen L., zagonel vittorina, Pressiani Tiziana, Ryu Min Hee, Venook Alan P., Hessel Colin, Borgman-Hagey Anne E., Schwab Gisela, Kelley Robin K.NEW ENGLAND JOURNAL OF MEDICINE79.26
Addition of dose-intensified doxorubicin to standard chemotherapy for rhabdomyosarcoma (EpSSG RMS 2005): a multicentre, open-label, randomised controlled, phase 3 trialGroup European paediatric Soft tissue sarcoma Study, Bisogno Gianni, Jenney Meriel, Bergeron Christophe, Gallego Melc¿¿n Soledad, Ferrari Andrea, Oberlin Odile, Carli Modesto, Stevens Michael, Kelsey Anna, De Paoli Angela, Gaze Mark N, Martelli Helene, Devalck Christine, Merks Johannes H, Ben-Arush Myriam, Glosli Heidi, Chisholm Julia, Orbach Daniel, Minard-Colin Veronique, De Salvo Gian LucaLANCET ONCOLOGY36.421
Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS) a multicentre, open-label, randomised phase 3 trialDummer Reinhard, Ascierto Paolo A, Gogas Helen J, Arance Ana, Mandala Mario, Liszkay Gabriella, Garbe Claus, Schadendorf Dirk, Krajsova Ivana, Gutzmer Ralf, chiarion sileni vanna, Dutriaux Caroline, de Groot Jan Willem B, Yamazaki Naoya, Loquai Carmen, Moutouh-de Parseval Laure A, Pickard Michael D, Sandor Victor, Robert Caroline, Flaherty Keith TLANCET ONCOLOGY36.421
Health-related quality of life and patient-centred outcomes with olaparib maintenance after chemotherapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT Ov-21) a placebo-controlled, phase 3 randomised trialFriedlander Michael, Gebski Val, Gibbs Emma, Davies Lucy, Bloomfield Ralph, Hilpert Felix, Wenzel Lari B., Eek Daniel, Rodrigues Manuel, Clamp Andrew, Penson Richard T., Provencher Diane, Korach Jacob, Huzarski Tomasz, Vidal Laura, Salutari Vanda, Scott Clare, NICOLETTO MARIA ORNELLA, Tamura Kenji, Espinoza David, Joly Florence, Pujade-Lauraine EricLANCET ONCOLOGY36.421
Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067) 4-year outcomes of a multicentre, randomised, phase 3 trialHodi Frank Stephen, chiarion sileni vanna, Gonzalez Rene, Grob Jean-Jacques, Rutkowski Piotr, Cowey Charles Lance, Lao Christopher D, Schadendorf Dirk, Wagstaff John, Dummer Reinhard, Ferrucci Pier Francesco, Smylie Michael, Hill Andrew, Hogg David, Marquez-Rodas Ivan, Jiang Joel, Rizzo Jasmine, Larkin James, Wolchok Jedd DLANCET ONCOLOGY36.421
Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trialDummer R., Ascierto P.A., Gogas H.J., Arance A., Mandala M., Liszkay G., Garbe C., Schadendorf D., Krajsova I., Gutzmer R., chiarion sileni vanna, Dutriaux C., de Groot J.W.B., Yamazaki N., Loquai C., Moutouh-de Parseval L.A., Pickard M.D., Sandor V., Robert C., Flaherty K.T.LANCET ONCOLOGY36.421
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224) a non-randomised, open-label phase 2 trialKEYNOTE-224 investigators Gruppo, Zhu Andrew X, Finn Richard S, Edeline Julien, Cattan Stephane, Ogasawara Sadahisa, Palmer Daniel, Verslype Chris, zagonel vittorina, Fartoux Laetitia, Vogel Arndt, Sarker Debashis, Verset Gontran, Chan Stephen L, Knox Jennifer, Daniele Bruno, Webber Andrea L, Ebbinghaus Scot W, Ma Junshui, Siegel Abby B, Cheng Ann-Lii, Kudo MasatoshiLANCET ONCOLOGY36.421
Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA) a multicentre, open-label, randomised, controlled, phase 2 trialLOMBARDI GIUSEPPE, De Salvo Gian Luca, Brandes Alba Ariela, Eoli Marica, Rud¿¿ Roberta, Faedi Marina, Lolli Ivan, Pace Andrea, Daniele Bruno, Pasqualetti Francesco, Rizzato Simona, Bellu Luisa, Pambuku Ardi, Farina Miriam, Magni Giovanna, Indraccolo Stefano, Gardiman Marina Paola, Soffietti Riccardo, zagonel vittorinaLANCET ONCOLOGY36.421
Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC) a final analysis of a phase 3, randomised, placebo-controlled studyRimassa Lorenza, Assenat Eric, Peck-Radosavljevic Markus, Pracht Marc, zagonel vittorina, Mathurin Philippe, Rota Caremoli Elena, Porta Camillo, Daniele Bruno, Bolondi Luigi, Mazzaferro Vincenzo, Harris William, Damjanov Nevena, Pastorelli Davide, Reig Mar¿¿a, Knox Jennifer, Negri Francesca, Trojan J¿¿rg, L¿¿pez L¿¿pez Carlos, Personeni Nicola, Decaens Thomas, Dupuy Marie, Sieghart Wolfgang, Abbadessa Giovanni, Schwartz Brian, Lamar Maria, Goldberg Terri, Shuster Dale, Santoro Armando, Bruix JordiLANCET ONCOLOGY36.421
BRAF V600E Confers Male Sex Disease-Specific Mortality Risk in Patients With Papillary Thyroid CancerWang Fei, Zhao Shihua, Shen Xiaopei, Zhu Guangwu, Liu Rengyun, Viola David, Elisei Rossella, Puxeddu Efisio, Fugazzola Laura, Colombo Carla, Jarzab Barbara, Czarniecka Agnieszka, Lam Alfred K, Mian Caterina, Vianello Federica, Yip Linwah, Riesco-Eizaguirre Garcilaso, Santisteban Pilar, O'Neill Christine J, Sywak Mark S, Clifton-Bligh Roderick, Bendlova Bela, S¿¿korov¿¿ Vlasta, Wang Yangang, Xing MingzhaoJOURNAL OF CLINICAL ONCOLOGY26.36
Demographic and Treatment Variables Influencing Outcome for Localized Paratesticular Rhabdomyosarcoma: Results From a Pooled Analysis of North American and European Cooperative GroupsWalterhouse David O, Barkauskas Donald A, Hall David, Ferrari Andrea, De Salvo Gian Luca, Koscielniak Ewa, Stevens Michael C G, Martelli H¿¿l¿¿ne, Seitz Guido, Rodeberg David A, Shnorhavorian Margarett, Dasgupta Roshni, Breneman John C, Anderson James R, Bergeron Christophe, Bisogno Gianni, Meyer William H, Hawkins Douglas S, Minard-Colin VeroniqueJOURNAL OF CLINICAL ONCOLOGY26.36
Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal CancerOverman Michael J, Lonardi Sara, Wong Ka Yeung Mark, Lenz Heinz-Josef, Gelsomino Fabio, Aglietta Massimo, Morse Michael A, Van Cutsem Eric, McDermott Ray, Hill Andrew, Sawyer Michael B, Hendlisz Alain, Neyns Bart, Svrcek Magali, Moss Rebecca A, Ledeine Jean-Marie, Cao Z Alexander, Kamble Shital, Kopetz Scott, Andr¿¿ ThierryJOURNAL OF CLINICAL ONCOLOGY26.36
FOLFOX or CAPOX in Stage II to III Colon Cancer: Efficacy Results of the Italian Three or Six Colon Adjuvant TrialInvestigators TOSCA, Sobrero Alberto, Lonardi Sara, Rosati Gerardo, Di Bartolomeo Maria, Ronzoni Monica, Pella Nicoletta, Scartozzi Mario, Banzi Maria, Zampino Maria Giulia, Pasini Felice, Marchetti Paolo, Cantore Maurizio, Zaniboni Alberto, Rimassa Lorenza, Ciuffreda Libero, Ferrari Daris, zagonel vittorina, Maiello Evaristo, Barni Sandro, Rulli Eliana, Labianca RobertoJOURNAL OF CLINICAL ONCOLOGY26.36
Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected BRAF V600-Mutant Stage III MelanomaHauschild Axel, Dummer Reinhard, Schadendorf Dirk, Santinami Mario, Atkinson Victoria, Mandal¿¿ Mario, chiarion sileni vanna, Larkin James, Nyakas Marta, Dutriaux Caroline, Haydon Andrew, Robert Caroline, Mortier Laurent, Schachter Jacob, Lesimple Thierry, Plummer Ruth, Dasgupta Kohinoor, Haas Tomas, Shilkrut Mark, Gasal Eduard, Kefford Richard, Kirkwood John M, Long Georgina VJOURNAL OF CLINICAL ONCOLOGY26.36
Loss of Chromosome 18q11.2-q12.1 Is Predictive for Survival in Patients With Metastatic Colorectal Cancer Treated With Bevacizumabvan Dijk Erik, Biesma Hedde D, Cordes Martijn, Smeets Dominiek, Neerincx Maarten, Das Sudipto, Eijk Paul P, Murphy Verena, Barat Anna, Bacon Orna, Prehn Jochen H M, Betge Johannes, Gaiser Timo, Fender Bozena, Meijer Gerrit A, McNamara Deborah A, Klinger Rut, Koopman Miriam, Ebert Matthias P A, Kay Elaine W, Hennessey Bryan T, Verheul Henk M W, Gallagher William M, O'Connor Darran P, Punt Cornelis J A, Loupakis Fotios, Lambrechts Diether, Byrne Annette T, van Grieken Nicole C T, Ylstra BaukeJOURNAL OF CLINICAL ONCOLOGY26.36

Source: IOV Scientific library